<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590355</url>
  </required_header>
  <id_info>
    <org_study_id>ORATOR</org_study_id>
    <nct_id>NCT01590355</nct_id>
  </id_info>
  <brief_title>A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)</brief_title>
  <acronym>ORATOR</acronym>
  <official_title>A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The historical standard treatment for early-stage squamous cell carcinoma of the oropharynx
      is radiation therapy. Some patients require chemotherapy with the radiation, and some
      patients require surgery if the tumour or lymph nodes have not responded after radiation.

      This study will compare radiation therapy with a new surgical treatment called transoral
      robotic surgery (TORS). TORS is a new surgical approach using a robot to assist the surgeon
      in removing the tumour, potentially with fewer side effects than older surgical techniques.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1-year post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At the end of 3 years and at the end of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At the end of 3 years and at the end of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at other time points</measure>
    <time_frame>Every 6 months for 5 years from 1st date of treament</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5 years from date of first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallowing Function</measure>
    <time_frame>5 years from date of first treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Early-Stage Squamous Cell Carcinoma of the Oropharynx</condition>
  <arm_group>
    <arm_group_label>Radiotherapy plus or minus Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy plus or minus chemotherapy with surgical treatment for salvage of persistent disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transoral Robotic Surgery + Neck Dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transoral robotic excision will be carried out using the da Vinci surgical robot. The spatula cautery will be used to remove the tumours with 1 cm margins. At the time of surgery circumferential margins will be taken and sent for frozen section analysis. The resection will proceed until negative margins are obtained if feasible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks</description>
    <arm_group_label>Radiotherapy plus or minus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transoral Robotic Surgery + Neck Dissection</intervention_name>
    <description>Transoral robotic excision will be carried out using the da Vinci surgical robot.</description>
    <arm_group_label>Transoral Robotic Surgery + Neck Dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or older

          -  willing to provide informed consent

          -  ECOG performance status 0-2

          -  Histologically confirmed squamous cell carcinoma primary rumour site in the oropharynx
             (includes tonsil, soft palate, base of tongue, walls of oropharynx)

          -  Tumour stage:T1 or T2, with likely negative resections at surgery

          -  Nodal stage: N0, N1, or N2 (less than or equal to 4 cm in maximum dimension in any
             plane, on either side of the neck), without extranodal extension on pre-randomization
             imaging.

          -  Patient assessed at head and neck multidisciplinary clinic (with assessment by
             radiation oncologist and surgeon) and presented at multidisciplinary tumour board
             prior to randomization.

        Exclusion Criteria:

          -  Serious medical comorbidities or other contraindications to radiotherapy, chemotherapy
             or surgery

          -  Prior history of head and neck cancer within 5 years

          -  Prior head and neck radiation at any time

          -  Metastatic disease

          -  Inability to attend full course of radiotherapy or follow-up visits

          -  Neck disease with unknown primary site

          -  Prior invasive malignant disease unless disease-free for at least 5 years or more,
             with the exception of non-melanoma skin cancer

          -  unable or unwilling to complete QoL questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Palma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Regional Cancer Program of the Lawson Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Nichols, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Regional Cancer Program of the Lawson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program of the Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>David Palma</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

